AorTech's Staying Power
This article was originally published in Start Up
Executive Summary
With its flagship product, a polyurethane-based heart valve, not yet in human trials, AorTech is in-licensing revenue-producing products, both in its core area of heart valves and in non-core critical care as well. The company hopes the strategy will give it the wherewithal to withstand a difficult financing environment and the doldrums of development.